{"id":3810,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/carmustine-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"carmustine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/carmustine-txt\/","title":{"rendered":"Carmustine.txt"},"content":{"rendered":"

Carmustine<\/h1>\n

CLINICAL USE <\/H3>
\nAlkylating agent:<\/p>\n
  • Myeloma, lymphoma and brain tumours

    DOSE IN NORMAL RENAL FUNCTION <\/H3>150\u2013200 mg\/m2 as a single dose or 75\u2013100 mg\/m2 on 2 consecutive days every 6 weeks Implants: 7.7mg, maximum 8 implants

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :214.1<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :77<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 60\u201370<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :3.25<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :22 minutes\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\n
  • 3 mL of the supplied diluent (absolute ethanol) then add 27 mL of sterile water for injection\n
  • This solution may be further diluted with sodium chloride 0.9% or glucose 5% for injection

    Route <\/H4>IV

    Rate of Administration <\/H4>\n
  • Administer by IV drip over a period of 1\u20132 hours

    Comments<\/H4>\n
  • Therapy should not be repeated before 6 weeks\n
  • Can further dilute the reconstituted solution with 500 mL of sodium chloride 0.9% or glucose 5%

    OTHER INFORMATION <\/H4>\n
  • Renal abnormalities, e.g. a decrease in kidney size: progressive azotaemia and renal failure have been reported in patients receiving large cumulative doses after prolonged therapy\n
  • Partially metabolised to active species by liver microsomal enzymes, which have a long T\u00bd. It is thought that the antineoplastic activity may be due to metabolites. Approximately 30% of a dose is excreted in the urine after 24 hours, and 60\u201370% of the total dose after 96 hours. About 10% is excreted as respiratory CO2. Terminal half-life of the metabolites are about 1 hour.
    \n","protected":false},"excerpt":{"rendered":"

    Carmustine CLINICAL USE Alkylating agent: Myeloma, lymphoma and brain tumours<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3810","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3810"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3810\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}